论文部分内容阅读
目的:观察紫杉醇联合铂类同步放疗、化疗治疗中晚期宫颈癌的临床效果。方法:选取我院2012年12月至2013年12月收治的62例中晚期宫颈癌患者作为研究对象,根据FIGO标准分期,Ⅱb期19例,Ⅲa期7例,Ⅲb期36例,采用紫杉醇联合顺铂同步放疗、化疗治疗均接受手术治疗模式,治疗结束后,观察近期疗效,并通过复查和电话随访观察患者的不良反应。结果:62例患者中,完全缓解患者27例(43.5%),部分缓解患者24例(38.7%),无变化患者8例(12.9%),进展患者3例(4.8%),有效率(CR+PR)为82.2%。治疗过程中的不良反应主要有胃肠道反应、骨髓抑制、放射性肠炎等,经及时治疗均得到较好缓解,本组观察未出现过敏反应和治疗相关性死亡。结论:对于晚期宫颈癌,多采用紫杉醇联合铂类同步放疗、化疗治疗模式,近期疗效较好,不良反应患者均可耐受。
Objective: To observe the clinical effect of paclitaxel combined with platinum-based synchronous radiotherapy and chemotherapy in the treatment of advanced cervical cancer. Methods: Sixty-two patients with advanced cervical cancer who were treated in our hospital from December 2012 to December 2013 were enrolled in this study. According to FIGO standard staging, 19 cases were stage Ⅱb, 7 cases were stage Ⅲa and 36 cases were stage Ⅲb. The patients were treated with paclitaxel Cisplatin synchronous radiotherapy and chemotherapy were received surgical treatment mode, after treatment, observe the short-term efficacy, and by reviewing and telephone follow-up observation of adverse reactions in patients. Results: Of the 62 patients, 27 (43.5%) had complete remission, 24 (38.7%) had partial remission, 8 (12.9%) had no change, 3 + PR) was 82.2%. Adverse reactions in the course of treatment mainly gastrointestinal reactions, myelosuppression, radiation enteritis and so on, were promptly treated were better relief, the group observed no allergic reaction and treatment-related deaths. Conclusion: For advanced cervical cancer, the use of paclitaxel combined with platinum-based concurrent radiotherapy and chemotherapy treatment mode, the recent curative effect is good, patients with adverse reactions can be tolerated.